Skip to content

Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02016430
Acronym
GRADY
Enrollment
170
Registered
2013-12-20
Start date
2014-04-04
Completion date
2026-12-01
Last updated
2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk Factor, Dietary Modification

Keywords

TMAO, Gut Flora, Dietary Intervention, Choline, Carnitine

Brief summary

Our group has recently identified the association between gut-flora-mediated carnitine and phosphatidylcholine metabolism, specifically trimethylamine-N-oxide (TMAO), and cardiovascular risk. This study investigates the ability for dietary intervention to modulate TMAO levels.

Detailed description

This is a pilot human study to characterize the relationship between gut flora-associated TMAO generation and dietary intervention. The investigators hypothesize that tailored dietary interventions may help to reduce the ability for gut flora to generate TMAO in individuals with elevated TMAO levels. Specific aims include: 1. To investigate the proportion of subjects with persistently elevated circulating TMAO levels. 2. To compare the amount of TMAO generated from gut flora using stable-isotope-labelled choline, carnitine, and betaine in subjects with elevated versus normal circulating TMAO levels. 3. To evaluate the effect of dietary interventions on the amount of TMAO generated from gut flora using stable-isotope-labelled choline, carnitine, and betaine in subjects with elevated circulating TMAO levels.

Interventions

BEHAVIORALMeLT Dietary intervention

Mediterranean diet containing food with low TMAO content.

BEHAVIORALTLC Dietary intervention

Standard American Heart Association (AHA) recommendations for dietary counseling.

BEHAVIORALMeLT dietary intervention with TMAO

Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Cohort 1 Inclusion criteria: * Men and women age 18 years or above. * Elevated TMAO metabolizers (\>5 µM) based on screening test and/or eGFR \< 60 at most recent measurement. * Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study. * Willing to sign the consent form and follow the study protocol, which includes a 12-week dietary modification. Cohort 2 Inclusion criteria: * Men and women age 18 years or above. * Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study. * Willing to sign the consent form and follow the study protocol. * eGFR values ranging from 16-59 Cohort 3 Inclusion criteria: * Men and women age 18 years or above. * Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study. * Willing to sign the consent form and follow the study protocol.

Exclusion criteria

(all cohorts): * Significant chronic illness or end-organ dysfunction, including known history of uncompensated heart failure, renal failure, pulmonary disease, hematologic diseases. * Active infection or received antibiotics within 2 months of study enrollment * Use of over-the-counter probiotic within past month, or ingestion of yogurt within past 7 days * Having undergone bariatric procedures or surgeries such as gastric banding or bypass. * Pregnancy. * Any condition which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial

Design outcomes

Primary

MeasureTime frameDescription
Change in TMAO levelFrom baseline to 12 weeks follow-upThe change in TMAO concentration measured in blood samples

Countries

United States

Contacts

CONTACTJennifer Wilcox, BA
kirsopj@ccf.org216-636-6153
CONTACTValesha Province, MA
provinv@ccf.org216-636-6153
PRINCIPAL_INVESTIGATORW. H. Wilson Tang, MD

The Cleveland Clinic

PRINCIPAL_INVESTIGATORStanley L. Hazen, MD, PhD

The Cleveland Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026